Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Historical Valuation Ratios (Summary)

Merck & Co. Inc., historical price multiples (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Price to earnings (P/E)
Price to operating profit (P/OP)
Price to sales (P/S)
Price to book value (P/BV)

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).


The analysis of the provided financial ratios reveals several notable trends over the observed periods.

Price to Earnings (P/E) Ratio
The P/E ratio data, available from March 31, 2020 onwards, exhibits significant volatility. Initial values range from approximately 26.72 to 34.23 during 2020 and early 2021 before experiencing a marked decline to a low around 13.36 by the end of 2022. Subsequently, the ratio increases sharply, peaking at an unusually high value of 893.99 in September 2023, followed by a rapid decrease to values near 12 by mid-2025. This pattern suggests episodic fluctuations in market expectations of earnings performance or earnings volatility, with a potential outlier or data anomaly in late 2023. The general trend indicates periods of heightened optimism or speculation followed by rapid corrections.
Price to Operating Profit (P/OP) Ratio
The P/OP ratio follows a similar broad trend to the P/E ratio, with data also starting from March 31, 2020. It begins with moderate values around 23.89 to 38.03 in 2020 and early 2021, then declines to lows near 11.72 by late 2022. A sharp surge occurs in 2023, with a peak at approximately 138.56 in March 2024, before correcting downward again to levels near 10 by mid-2025. This ratio's volatility mirrors that of the P/E ratio, reinforcing the interpretation of fluctuating market assessments of operating profitability relative to price, and perhaps reflecting operational performance instability or shifting market sentiment.
Price to Sales (P/S) Ratio
The P/S ratio presents a more stable movement compared to P/E and P/OP, ranging mostly between 3.17 and 5.43. It shows a gradual increase from around 3.93 in early 2020 to a peak above 5.4 around late 2023 and early 2024, followed by a moderate decline toward 3.17 by mid-2025. This suggests steady investor valuation of sales relative to price, with moderate market confidence in revenue generation ability, exhibiting less extreme fluctuations compared to earnings or operating profit ratios.
Price to Book Value (P/BV) Ratio
The P/BV ratio shows a slow declining trend over the full period, beginning near 7.43 in early 2020 and falling steadily to 4.12 by mid-2025. There are some minor fluctuations, and a temporary rise around late 2023 to early 2024, reaching approximately 8.68, but the general tendency is downward. This pattern may indicate a gradual decrease in market valuation relative to book value, implying either improvements in book value outpacing market price or investor reassessment of asset values or growth prospects.

In summary, the ratios reflect different aspects of valuation and market sentiment. The earnings and operating profit based ratios demonstrate heightened volatility with sharp peaks and troughs, indicating fluctuating investor confidence possibly tied to earnings reports or operating results shocks. The price to sales ratio remains comparatively stable with moderate variation, while the price to book value shows a general downward trajectory, potentially signaling a shift in how the market values tangible or net assets of the company over time. The presence of extreme spikes, especially in 2023, could warrant further investigation into underlying events or accounting impacts during this period.


Price to Earnings (P/E)

Merck & Co. Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
No. shares of common stock outstanding1
Selected Financial Data (US$)
Net income (loss) attributable to Merck & Co., Inc. (in millions)
Earnings per share (EPS)2
Share price1, 3
Valuation Ratio
P/E ratio4
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2025 Calculation
EPS = (Net income (loss) attributable to Merck & Co., Inc.Q2 2025 + Net income (loss) attributable to Merck & Co., Inc.Q1 2025 + Net income (loss) attributable to Merck & Co., Inc.Q4 2024 + Net income (loss) attributable to Merck & Co., Inc.Q3 2024) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Merck & Co. Inc. Quarterly or Annual Report.

4 Q2 2025 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =

5 Click competitor name to see calculations.


Share Price Trend
The share price exhibited a fluctuating pattern over the periods analyzed. Initially, from March 2020 to December 2020, the price showed moderate volatility, starting at $77.12 and declining to $74.62 by year-end. During 2021, the price recovered, peaking at $81.61 in September before dropping to $76.32 in December. A notable upward trend occurred throughout 2022 and into early 2023, with the price reaching its highest point of $128.84 in December 2023. Subsequently, the share price experienced a downward correction, decreasing steadily to $80.79 by June 2025. Overall, the price exhibited growth until late 2023, followed by a significant retracement.
Earnings Per Share (EPS) Development
EPS data began in March 2021, showing an initial value of $2.79, which slightly dipped to $2.2 by September 2021 before recovering to $2.85 at year-end. In 2022, EPS increased substantially, peaking at $6.54 in September and maintaining elevated levels through the year, ending at $6.02 in December. Early 2023 saw a gradual decline in EPS from $5.72 in March to notably lower values in the middle of the year, reaching a minimum of $0.14 in September 2023. This was followed by a recovery trend, with EPS climbing back to $6.78 by September 2024 and maintaining strong earnings into mid-2025. The EPS exhibited considerable volatility during 2023 but generally strengthened afterward.
Price-to-Earnings (P/E) Ratio Movement
P/E ratios were unavailable before March 2021. From the data, initial P/E was around 26.72 in March 2021, fluctuating between about 14.78 and 34.23 through 2021. During 2022, P/E values trended downward from 15.7 in June to 16.41 in December, showing a relatively stable valuation despite earnings increases. In 2023, there were extreme spikes, with the ratio reaching a peak of 893.99 in September, indicative of either drastically reduced earnings or elevated share prices. By December 2023, the P/E decreased but remained elevated at 140.05. Subsequently, the ratio normalized to values between 11.98 and 20.98 from early 2024 through mid-2025, reflecting a return to more typical valuation levels in line with EPS recovery and moderating share prices.

Price to Operating Profit (P/OP)

Merck & Co. Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
No. shares of common stock outstanding1
Selected Financial Data (US$)
Operating income (loss) (in millions)
Operating profit per share2
Share price1, 3
Valuation Ratio
P/OP ratio4
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2025 Calculation
Operating profit per share = (Operating income (loss)Q2 2025 + Operating income (loss)Q1 2025 + Operating income (loss)Q4 2024 + Operating income (loss)Q3 2024) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Merck & Co. Inc. Quarterly or Annual Report.

4 Q2 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =

5 Click competitor name to see calculations.


Share Price Trend
The share price demonstrated moderate fluctuations over the periods. Initially, from the first quarter of 2020 to the fourth quarter of 2020, the price showed a slight decline, moving from $77.12 down to $74.62. It experienced a recovery in 2021, peaking near $81.61 in the third quarter, and then fluctuated with an upward trend, reaching a notable high of $128.84 by the fourth quarter of 2023. Following this peak, the share price declined progressively into early 2025, settling near $80.79. Overall, the share price exhibited volatility with peaks around late 2023 and subsequent declines into 2025.
Operating Profit Per Share (OPPS) Dynamics
Starting from the first quarter of 2021, the operating profit per share showed considerable variability. It initially rose from $3.12 in the first quarter of 2021, then experienced a downward movement towards the third quarter of 2021 at $1.98. A strong recovery followed, with a peak of $7.46 in the third quarter of 2022. Subsequently, the OPPS maintained relatively high levels around $7.13 to $7.64 through 2023. However, a notable drop was observed in the fourth quarter of 2023 ($2.38) and the first quarter of 2024 ($0.93), before rebounding again to $8.02 by the second quarter of 2025. This pattern indicates periods of strong profitability punctuated by significant declines, followed by quick recoveries.
Price to Operating Profit Ratio (P/OP) Analysis
The P/OP ratio demonstrated significant volatility, inversely reflecting changes in operating profit per share relative to the share price. Lower ratios, observed notably during mid-2022 (around 11.72) to early 2023, correspond to periods of strong operating profitability and relatively stable share prices. Conversely, spikes in the P/OP occurred during quarters with sharply reduced operating profits, such as the fourth quarter of 2023 (44.67) and the first quarter of 2024 (138.56), indicating share price levels that were high relative to diminished operating earnings. Following these peaks, the ratio normalized back down to approximately 10–11 by mid-2025, consistent with improved operating profit performance and declining share prices.
Overall Summary and Insights
The data reflects substantial fluctuations in operational performance alongside corresponding market valuation adjustments. Operating profit per share exhibited cycles of growth and contraction, impacting the valuation multiples investors were willing to pay. The share price trend displays a strong upward movement culminating late 2023, followed by a downward correction into 2025. The inverse relationship between the P/OP ratio and operating profit per share emphasizes the sensitivity of market valuation to operating profitability. These dynamics suggest that periods of weakened operating profit exerted downward pressure on market confidence, leading to elevated valuation multiples and eventual price corrections.

Price to Sales (P/S)

Merck & Co. Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
No. shares of common stock outstanding1
Selected Financial Data (US$)
Sales (in millions)
Sales per share2
Share price1, 3
Valuation Ratio
P/S ratio4
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2025 Calculation
Sales per share = (SalesQ2 2025 + SalesQ1 2025 + SalesQ4 2024 + SalesQ3 2024) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Merck & Co. Inc. Quarterly or Annual Report.

4 Q2 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =

5 Click competitor name to see calculations.


Share Price Trends
The share price demonstrated significant volatility over the observed period. Initially, from March 2020 to December 2020, the price fluctuated within a range roughly between $74 and $81, showing no clear upward or downward trend. Beginning in early 2021, the share price showed an upward trajectory, reaching a peak near $128.84 in December 2023. However, from that peak onward, there was a notable decline, with share prices decreasing steadily to approximately $80.79 by June 2025. This pattern suggests a period of strong investor confidence and growth followed by a phase of retracement or market correction.
Sales per Share Patterns
Sales per share data are available from March 2021 onward and indicate a general upward trend throughout the period. Starting at $18.97 in March 2021, sales per share increased gradually with minor fluctuations, reaching approximately $25.47 by June 2025. This steady increase in sales per share reflects consistent revenue growth or enhanced operational efficiency over time.
Price-to-Sales (P/S) Ratio Analysis
The P/S ratio exhibits considerable fluctuations during the period of record. Initially, around March 2021, the ratio hovered in the range of 3.9 to 4.3, indicating moderate valuation relative to sales. From late 2022 through to 2023, there was a marked increase, peaking at 5.43 in December 2023, coinciding with the peak in the share price. This elevated P/S ratio suggests that the market was pricing the shares at a premium relative to sales, potentially reflecting strong growth expectations. However, following the peak, the P/S ratio declined steadily to around 3.17 by June 2025, paralleling the decrease in share price and suggesting a reversion to a more conservative valuation level relative to sales.
Integrated Insights
The rising sales per share indicate improving fundamental business performance or sales growth, while the share price and P/S ratio movements suggest that market sentiment experienced cycles of enthusiasm followed by correction. The peak in valuation ratios and share prices around late 2023 likely reflects heightened growth optimism, but the subsequent decline may imply reassessment of growth prospects or broader market pressures. Overall, the data portrays a company with improving operational metrics but subject to fluctuating market valuations over the analyzed timeframe.

Price to Book Value (P/BV)

Merck & Co. Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
No. shares of common stock outstanding1
Selected Financial Data (US$)
Total Merck & Co., Inc. stockholders’ equity (in millions)
Book value per share (BVPS)2
Share price1, 3
Valuation Ratio
P/BV ratio4
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2025 Calculation
BVPS = Total Merck & Co., Inc. stockholders’ equity ÷ No. shares of common stock outstanding
= ÷ =

3 Closing price as at the filing date of Merck & Co. Inc. Quarterly or Annual Report.

4 Q2 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =

5 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals several notable trends in share price, book value per share (BVPS), and their relationship through the price-to-book value (P/BV) ratio over the observed periods.

Share Price
The share price experienced fluctuations throughout the timeline. Initially, from March 2020 to December 2020, the price moved within a range of approximately $74.62 to $81.64, showing moderate volatility. A significant upward trend started in early 2021, with the share price reaching a peak of $128.84 in December 2023. However, following this peak, a steady decline was observed through to June 2025, where the price decreased to about $80.79. Overall, the share price demonstrated periods of growth interspersed with correction phases, culminating in a pronounced peak and subsequent downturn.
Book Value Per Share (BVPS)
The BVPS showed a general upward trend over the entire period. Starting from $10.38 in March 2020, it increased steadily, reaching $19.61 by June 2025. Some quarters presented slight decreases or plateaus—specifically around early to mid-2023 and late 2023—but these were temporary, and the overall progression remained positive. This indicates consistent growth in the company’s equity base on a per-share basis, reflecting accumulated retained earnings or asset appreciation.
Price-to-Book Value (P/BV) Ratio
The P/BV ratio exhibited an inverse relationship to BVPS and fluctuated significantly during the timeframe. Initially high in early 2020, with values around 7.4, it decreased to near 5 by late 2021, suggesting that share prices did not increase at the same pace as book value. Into 2023 and early 2024, the ratio increased again sharply, peaking at 8.68 in December 2023, indicating a higher market valuation relative to book value, coinciding with the share price peak. Following this high point, the ratio declined steadily to about 4.12 by June 2025, signaling that the share price adjusted downwards more sharply than the book value in the latter periods.

Overall, the data suggest strong underlying growth in the company's book value with greater volatility observed in share price valuation. The P/BV ratio's fluctuations emphasize varying market sentiments toward the stock, with phases of overvaluation around late 2023, followed by correction phases to more moderate valuation levels by mid-2025.